{
    "clinical_study": {
        "@rank": "8281", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Dual-therapy with a response-guided treatment duration with DEB025 200 mg BID and RBV"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Dual-therapy with a response-guided treatment duration with DEB025 300mg BID and RBV"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Experimental", 
                "description": "Dual-therapy with a response-guided treatment duration with DEB025 400 mg BID and RBV"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will explore the relationship of different DEB025 doses in combination with RBV\n      to pharmacokinetic, pharmacodynamic (i.e. viral load reduction) and safety profiles in\n      chronic hepatitis C GT 2 and 3 treatment na\u00efve patients."
        }, 
        "brief_title": "Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment na\u00efve Patients", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Liver Disease", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Liver Diseases", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent must be obtained before any assessment is performed.\n\n          2. No previous treatment for Hepatitis C infection (i.e. HCV treatment-na\u00efve)\n\n          3. Chronic hepatitis C  (G2 or G3)virus infection diagnosed\n\n        Exclusion criteria:\n\n          1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5\n             half-lives of that medication before enrollment.\n\n          2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical\n             classes\n\n          3. HBsAg positive\n\n          4. HIV positive.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970904", 
            "org_study_id": "CDEB025A2222", 
            "secondary_id": "2012-004185-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Dual-therapy with a response-guided treatment duration with DEB025 200 mg BID and RBV", 
                "intervention_name": "DEB025 200mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "Dual-therapy with a response-guided treatment duration with DEB025 300mg BID and RBV", 
                "intervention_name": "DEB025 300mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm C", 
                "description": "Dual-therapy with a response-guided treatment duration with DEB025 400mg BID and RBV", 
                "intervention_name": "DEB025 400mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Chronic hepatitis C,  DEB025, Alisporivir, ribavirin therapy, genotype 2/3 treatment naive patients.", 
        "lastchanged_date": "February 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10969"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duesseldorf", 
                        "country": "Germany", 
                        "zip": "40225"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "79106"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20246"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20099"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30625"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "zip": "24146"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50924"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "zip": "81377"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "W\u00fcrzburg", 
                        "country": "Germany", 
                        "zip": "97080"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "BO", 
                        "zip": "40138"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rozzano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20089"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "zip": "40138"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bialystok", 
                        "country": "Poland", 
                        "zip": "15-540"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland", 
                        "zip": "20-079"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland", 
                        "zip": "01 - 201"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "G\u00f6teborg", 
                        "country": "Sweden", 
                        "zip": "416 85"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lule\u00e5", 
                        "country": "Sweden", 
                        "zip": "SE-971 80"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden", 
                        "zip": "221 85"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malmo", 
                        "country": "Sweden", 
                        "zip": "SE-205 02"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "141 86"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Umea", 
                        "country": "Sweden", 
                        "zip": "901 85"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frimley", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "GU16 7UJ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B15 2TT"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "E1 1BB"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE5 9RS"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy", 
                "Poland", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment na\u00efve Patients", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "changes in viral load among 3 treatment arms", 
                "measure": "Pharmacodynamics (PD)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "number of patients with changes in vital signs and lab vaules in 3 treatment arms", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970904"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "number of patients who achieved SVR12 among 3 treatment arms", 
            "measure": "SVR12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after the end of treatment"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}